Tag:

Novo Nordisk

Latest Headlines

Latest Headlines

Novo Nordisk quells diabetes pricing fears with 2015 growth forecast

Novo Nordisk has made diabetes-minded investors very happy today. Rather than following Sanofi's discouraging announcement of flat sales expectations in the field next year, the Danish drugmaker said it's expecting growth in the high single digits.

Novo Nordisk walks back some U.S. optimism for its next-gen insulin

Novo Nordisk is sounding a more cautious tone on Tresiba, its once-rejected new insulin. After hinting at an accelerated trip back to the FDA for the long-acting diabetes treatment, the Danish drugmaker now says it could be another few years before the injection is ready for another shot at approval.

Novo hiring 90 workers for its new plant in New Hampshire

Novo Nordisk in August bought a plant in New Hampshire that Japan's Olympus Biologics was giving up. Now it is looking for people to help operate it.

Diabetes pricing war? Sanofi, Lilly and Novo each have their ideas

When Sanofi announced that its franchise would suffer next year because of U.S. payer contracts, the natural follow-up question was this: Does this mean a diabetes pricing war? If Sanofi had to boost its rebates to win coverage--which the company admits it did--then that means its rivals, including Eli Lilly and Novo Nordisk, have, too.

UPDATED: Who's the diabetes price-cutting culprit: Lilly, Sanofi or Novo?

Sanofi said Tuesday that its diabetes sales would be flat for 2015, thanks to payer contracts. Lantus, the company's top-selling drug with more than $7 billion in 2013 sales, was able to win reimbursement in 90% of the U.S. market, CEO Chris Viehbacher--departed as of today--said during the third-quarter earnings call. 

U.S. Attorney asks Novo Nordisk about plant in Denmark

Novo Nordisk says the U.S. Attorney in Massachusetts has subpoenaed it for information about potential manufacturing issues at a plant in Kalundborg.

U.S. Attorney subpoenas Novo for info on Denmark plant

Denmark-based Novo Nordisk said on Friday that it had received a subpoena from a U.S. Attorney who wants some info about its manufacturing operations at a plant in Kalundborg. But the company said it really has no idea why.

Report: Novo Nordisk to file for IT unit IPO in coming days

Novo Nordisk is reportedly set to unveil details of an IPO of its IT services business NNIT in the coming days. The Danish drugmaker has spent most of 2014 assessing whether to spin off the unit as an independent company.

Gilead, Allergan, Novo and Valeant chiefs make the list of world's top 10

Pharma CEOs are doing a pretty good job at the helm--at least where the Harvard Business Review is concerned.

Novo Nordisk blueprints its obesity R&D push in Seattle

Novo Nordisk has made it official: The Danish drugmaker is making a full-fledged go at obesity R&D, looking to build a Seattle hub and hire some investigators as it expands its research palate.